SLG
LFCR icon

Stanley-Laman Group’s Lifecore Biomedical LFCR Stock Holding History

Stanley-Laman Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-18,559
Closed -$195K – 294
2016
Q1 		$195K Sell
18,559
-17,159
-48% -$188K 0.04% 258
2015
Q4 		$423K Sell
35,718
-83
-0.2% -$1.02K 0.07% 244
2015
Q3 		$418K Buy
+35,801
New +$474K 0.09% 216

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stanley-Laman Group's LFCR Position: Q2 2016 in Review

Stanley-Laman Group sold out of Lifecore Biomedical (LFCR) in Q2 2016, closing a stake of 18,559 shares — an estimated $195K sold.

Stanley-Laman Group first reported a position in LFCR in Q3 2015 and held it in 3 quarters. The position peaked at $423K in Q4 2015. 97 funds tracked by Wall St. Rank hold LFCR as of Q2 2016.

  • Stanley-Laman Group reported no remaining Lifecore Biomedical position as of Q2 2016 after selling out during the quarter.
  • Stanley-Laman Group sold 18,559 Lifecore Biomedical shares in Q2 2016, an estimated $195K.
  • Stanley-Laman Group first reported a position in Lifecore Biomedical in Q3 2015 and held it in 3 quarters.
  • Stanley-Laman Group's Lifecore Biomedical position peaked at $423K in Q4 2015.
  • 97 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2016.

Based on Stanley-Laman Group's 13F filing for Q2 2016, filed 4 Aug 2016.